Premium
Clinical course of hepatitis C virus‐positive patients with decompensated liver cirrhosis in the era of direct‐acting antiviral treatment
Author(s) -
Maesaka Kazuki,
Sakamori Ryotaro,
Yamada Ryoko,
Tahata Yuki,
Oshita Masahide,
Hagiwara Hideki,
Sakakibara Mitsuru,
Tamura Shinji,
Hiramatsu Naoki,
Inada Masami,
Iio Sadaharu,
Ito Toshifumi,
Yakushijin Takayuki,
Doi Yoshinori,
Kodama Takahiro,
Hikita Hayato,
Tatsumi Tomohide,
Takehara Tetsuo
Publication year - 2021
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.13623
Subject(s) - medicine , hepatocellular carcinoma , decompensation , cirrhosis , gastroenterology , hepatitis c virus , cohort , hepatitis c , virus , immunology
Aim The aim of the present study was to investigate the clinical course in hepatitis C virus (HCV)‐positive patients with decompensated liver cirrhosis after direct‐acting antivirals (DAAs) have been used for HCV infection. Methods This multicenter study prospectively analyzed a registered cohort composed of 73 HCV‐positive patients with decompensated cirrhosis who attended our 11 institutions between January 2018 and July 2018. Prognoses, including changes in the liver reserve, hepatocellular carcinoma (HCC), decompensation events, and survival, were analyzed up to July 2020, as was the initiation of DAA treatment. Results Sixty‐four (87.7%) and nine (12.3%) patients had Child–Pugh class (C‐P) B and C at baseline, respectively. Within 2 years after enrollment, 17 patients (23.3%) received treatment with DAAs, and 31 patients (42.5%) developed uncontrolled HCC, switched to palliative care, or died. Patients who received DAA treatment were significantly younger and had significantly higher alanine aminotransferase levels and lower platelet counts than the patients who did not receive DAA treatment. The rates of overall survival, cumulative HCC occurrence, and cumulative hospitalization for any hepatic decompensation event at 2 years were 64.8%, 13.1%, and 65.6%, respectively. Overall survival was significantly shorter and the HCC occurrence and hospitalization rates were significantly higher in C‐P C patients than in C‐P B patients. Conclusions Among HCV‐positive patients with decompensated cirrhosis, approximately one‐fourth received DAA treatment, but more than 40% of the patients lost the opportunity for treatment with DAAs.